GlassScriptPhysician profile
Trisha Jayantilal Patel
NPI 1053731927
$2,565.74
in general payments reported to CMS, 2019-2025
31 companies · $263 in 2025
The $263 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $234 · 2021: $31.64 · 2022: $480 · 2023: $42.59 · 2024: $970 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $701 · Consulting Fee: $540 · Education: $34.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $701.28 |
| Consulting Fee | $540.00 |
| Education | $34.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,020.00 | 2022-2024 | O-Arm |
| Abbvie INC. | $217.74 | 2019-2025 | |
| Leo Pharma INC. | $216.85 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $132.30 | 2019-2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $114.86 | 2024-2025 | |
| Amgen INC. | $108.60 | 2019-2025 | Otezla, Otezla |
| Celgene Corporation | $64.85 | 2019 | |
| Genentech USA, INC. | $64.60 | 2024 | Lunsumio, Polivy, Columvi |
| Exelixis INC. | $59.95 | 2024 | Cabometyx |
| Ucb, INC. | $59.06 | 2019 | |
| Genzyme Corporation | $50.18 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $34.65 | 2024 | Ultomiris |
| Vertex Pharmaceuticals Incorporated | $32.13 | 2025 | |
| Merck Sharp & Dohme LLC | $30.25 | 2025 | Keytruda |
| Janssen Biotech, INC. | $28.54 | 2024 | Akeega, Balversa, Erleada |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $27.43 | 2024 | |
| Genmab U.S., INC. | $25.25 | 2024 | Epkinly |
| Karyopharm Therapeutics INC. | $24.63 | 2024 | Xpovio |
| Dusa Pharmaceuticals, INC. | $23.80 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.78 | 2024 | |
| Avanos Medical | $21.82 | 2025 | Generator |
| Vyne Pharmaceuticals INC. | $20.97 | 2020 | |
| Stemline Therapeutics INC. | $20.95 | 2024 | Orserdu |
| Next Science LLC | $20.68 | 2020 | |
| Mayne Pharma Commercial LLC | $19.51 | 2019 | |
| Tactile Systems Technology INC | $19.00 | 2025 | Flexitouch Plus, Nimbl |
| Incyte Corporation | $18.96 | 2023 | Opzelura |
| Takeda Pharmaceuticals U.S.A., INC. | $17.88 | 2024 | Fruzaqla |
| Taiho Oncology, INC. | $17.03 | 2024 | |
| Lilly USA, LLC | $15.25 | 2020 | |
| Stryker Corporation | $15.24 | 2025 | Spy-Phi System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trisha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.